Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects
FEMS Microbiology Reviews · 13.11.2026
DOI: 10.1093/femsre/fuag059 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEMS Microbiology Reviews, online erschienen am 13.11.2026. Verfasst von Olga Pacios Santamaría und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of British Columbia. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review highlights the significant potential of mRNA-lipid nanoparticle (LNP) technology for application in bacterial vaccines, with a long-term goal to provide critical tools in controlling problematic microbial infections regardless of their antimicrobial resistance (AMR) profile. The current landscape of bacterial vaccine development, including methods for identification of candidate antigens, are discussed along with emerging design principles for LNP delivery systems. We focus on mRNA-LNP systems for delivery of bacterial vaccine antigens in large part due to their extensive clinical validation, compatibility with reverse vaccinology, and growing prominence in modern vaccinology. Attention is also given to emerging opportunities to develop effective tools to combat severe infections, particularly those caused by AMR bacterial infections. Specific advantages and challenges of RNA-based vaccine platforms and LNP delivery systems compared to other vaccine modalities including strategies are highlighted, with a focus on particular strengths in conserved antigen identification via genome sequencing and recent advances in optimizing LNP composition for induction of strongly protective immunity for vaccine delivery. We argue that mRNA-LNP technology combined with reverse vaccinology approaches has the potential to improve and accelerate bacterial vaccine development, particularly for broadly protective immunity less dependent on bacterial strain surface composition and which are entirely dependent on host immunity, making them agnostic to the issue of antimicrobial resistance.
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, University of British Columbia.
- Polymorphic Biosciences Inc, 2665 East Mall, Vancouver, BC V6T 1Z4, Canada.
- Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia.
- Division of Critical Care Medicine, Department of Medicine, University of British Columbia.
ORCID-Profile: Olga Pacios Santamaría
Zitieren
APA
Santamaría, O. P., Khan, M. M., Dezfouli, E. A., Brimacombe, C. A., Cullis, P. R., & Russell, J. A. (2026). Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects. FEMS Microbiology Reviews. https://doi.org/10.1093/femsre/fuag059
Vancouver
Santamaría OP, Khan MM, Dezfouli EA, Brimacombe CA, Cullis PR, Russell JA. Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects. FEMS Microbiology Reviews. 2026. doi:10.1093/femsre/fuag059
BibTeX
@article{Santamara2026,
author = {Santamaría, Olga Pacios and Khan, Muhammad Muzamil and Dezfouli, Ehsan Ansari and Brimacombe, Cedric A and Cullis, Pieter R and Russell, James A},
title = {Engineering mRNA-Lipid nanoparticle (LNP) vaccines against multidrug resistant bacteria: current and future prospects},
journal = {FEMS Microbiology Reviews},
year = {2026},
doi = {10.1093/femsre/fuag059}
}
EUVIMED